Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer CEO: spin-off more likely for animal health

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/12/2012 | 03:47pm CEST
View of Belgian headquarters of US pharmaceutical giant Pfizer in Brussels

LONDON (Reuters) - Pfizer Inc (>> Pfizer Inc.) is more likely to spin off its animal health unit than sell it outright, reflecting the expected investor appeal of such a large standalone business, its chief executive said on Monday.

LONDON (Reuters) - Pfizer Inc (>> Pfizer Inc.) is more likely to spin off its animal health unit than sell it outright, reflecting the expected investor appeal of such a large standalone business, its chief executive said on Monday.

No final decision has been taken but Ian Read told Reuters there were clear attractions for shareholders in a tax-free spinoff of the operation, which is the biggest in the industry.

"I would probably handicap animal health as more likely to be a spin than a sale," the CEO of the world's biggest drugmaker said in an interview in London.

Read, who took over as Pfizer chief in December 2010 at a challenging time, is shrinking the group by divesting non-core businesses, including veterinary medicine and infant nutrition.

Pfizer is losing billions of dollars of revenue from cholesterol blockbuster Lipitor, which is now off patent in many markets, although Read said he hopes to carve out a new future for the medicine as an over-the-counter (OTC) product.

The nutrition business is widely expected to be sold outright for around $10 billion. Bidders were asked to submit offers last week, with Nestle SA (>> Nestle SA) and a partnership of Danone SA and Mead Johnson Nutrition Co (>> Mead Johnson Nutrition CO) seen as frontrunners.

The process for animal health, however, is less well advanced and the case for a sale less obvious. Pfizer faces a hefty tax bill if it sells outright and any buyer would also faces substantial antitrust hurdles.

"It's the largest animal health business and it would stand alone as an individual company. There's huge interest among investors to own a company like that," Read said.

"With nutritional there are lots of companies that are already in the nutritional business and have it as a major development area."

Speculation about a possible sale of animal health, which analysts believe could be worth $15-20 billion, was fuelled last week by reports that Novartis AG (>> Novartis AG) had made an approach that was rebuffed by Pfizer, while Bayer AG (>> Bayer AG) was also weighing a move.

The plans to dispose of both units, which Pfizer has said would be completed between July 2012 and July 2013, follows a far-reaching review and a decision to focus on core pharmaceutical operations.

The outcome of that review was to focus on five core areas of drug research, while maintaining a strong presence in generic and OTC medicines.

Read said Pfizer hoped to introduce a non-prescription form of Lipitor, but this would not happen in the short term. Pfizer is currently discussing the issue with the Food and Drug Administration, which is seeking public comment on the idea of making more medicines available OTC.

"We would like to sell it over the counter. We're in discussions and development with the FDA on that," Read said.

In the past, Pfizer has been a mergers and acquisitions machine, snapping up smaller rivals and partners to build out its portfolio.

It will continue to look for bolt-on acquisitions, including deals that could be "multiples" of 2010's $3.6 billion purchase of King Pharmaceuticals, Read said. But he did not see a need for another large-scale deal like the $67 billion purchase of Wyeth in 2009.

Asked about the possibility of buying out Bristol-Myers Squibb Co (>> Bristol Myers Squibb Co.), its partner on promising anti-clotting drug Eliquis, Read said: "I'm not sure that would create shareholder value. I think the partnership is working very well."

(Editing by Chris Wickham)

By Ben Hirschler and Kate Kelland

Stocks mentioned in the article
ChangeLast1st jan.
BAYER -0.60% 99 Delayed Quote.-4.23%
BRISTOL-MYERS SQUIBB COMPANY -0.85% 51.17 Delayed Quote.-14.65%
MEAD JOHNSON NUTRITION CO 0.00%-End-of-day quote.0.00%
NESTLÉ -0.27% 75.2 Delayed Quote.-10.02%
NOVARTIS -1.55% 76.08 Delayed Quote.-6.21%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
04/20GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
04/20MONSANTO : Russian nod moves Bayer closer to wrapping up Monsanto deal
RE
04/20BAYER : Gains Russian Approval for Monsanto Deal
DJ
04/20BAYER : Temasek subscribes to capital increase and acquires approximately 3.6 pe..
AQ
04/20RUSSIA GIVES GREEN LIGHT TO BAYER'S : Ifax
RE
04/18BAYER AKTIENGESELLSCHAFT : Release according to Article 41 of the WpHG [the Germ..
EQ
04/18BAYER : commits to provide innovative vector control solutions to help eradicate..
PU
04/17EASTON PHARMACEUTICALS : Announces BAYER Agreement Update
AQ
04/17BAYER : Shareholder Temasek to Increase Share Capital -- Update
DJ
04/17BAYER : Temasek subscribes to capital increase and acquires approximately 3.6 pe..
AQ
More news
News from SeekingAlpha
04/20Bayer wins Russian approval for Monsanto deal 
04/17Germany to go forward with plans to restrict Monsanto weedkiller 
04/17Bayer's ILDR2 inhibitor shows encouraging action in preclinical studies, disc.. 
04/17The U.S. Approves Bayer And Monsanto's Merger 
04/12VERASTEM : A Solid Player On A Crowded Field 
Financials (€)
Sales 2018 35 542 M
EBIT 2018 7 319 M
Net income 2018 4 811 M
Debt 2018 6 823 M
Yield 2018 2,83%
P/E ratio 2018 17,98
P/E ratio 2019 15,67
EV / Sales 2018 2,53x
EV / Sales 2019 2,36x
Capitalization 82 930 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 118 €
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-4.23%102 353
JOHNSON & JOHNSON-8.59%342 627
PFIZER0.75%217 064
NOVARTIS-6.21%213 465
ROCHE HOLDING LTD.-12.17%193 713
MERCK AND COMPANY4.21%158 813